TURKISH JOURNAL OF ONCOLOGY 2022 , Vol 37 , Num 4
Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib
İzzet DOĞAN1,Nijat KHANMAMMADOV1,Nail PAKSOY1,Ferhat FERHATOĞLU1,Esra AYDIN1,Sezai VATANSEVER1,Pınar SAİP1,Adnan AYDINER1
1Deparment of Medical Oncology, İstanbul University, Institute of Oncology, Istanbul-Türkiye DOI : 10.5505/tjo.2022.3608 OBJECTIVE
ROS1 positivity is seen in 1-2% of patients with metastatic lung cancer. Targeted drugs such as crizotinib, lorlatinib, and entrectinib are used in the treatment. We aimed to evaluate the efficacy of crizotinib and the prognosis of patients with ROS1 fusion-positive metastatic non-small cell lung cancer (NSCLC) in this study.

METHODS
We analyzed data of the advanced NSCLC patients with ROS1 mutation retrospectively. We determined the clinicopathological features of the patients. We evaluated the parameters affecting the prognosis with survival analyzes.

RESULTS
The research enlisted the participation of 21 patients. Median progression-free survival with crizotinib treatment was found 26.1 (95% Confidence interval [CI], 8.1-44.1) months. Median overall survival was 35.2 (95% CI, 13.5-56.9) months. Treatment-related Grade 1-2 adverse effects were observed in 9 (42.9%) patients and Grade 3-4 adverse effects were detected in 1 (4.8%) patient. Clinicopathological parameters affecting survival were evaluated; age (p=0.02) and liver metastasis (p=0.03) were defined as prognostic parameters. ROS1 positivity rate (p=0.08) was not found to be a prognostic factor.

CONCLUSION
In patients with ROS1 fusion-positive metastatic NSCLC, crizotinib was shown to be both efficacious and safe. We also found that in this patient group, age and the existence of liver metastases are prognostic factors. Keywords : Crizotinib; non-small cell lung cancer; prognosis; ROS1 fusion